The use of stem cells in regenerative medicine for Parkinson's and Huntington's Diseases.
Identifieur interne : 000F79 ( Ncbi/Merge ); précédent : 000F78; suivant : 000F80The use of stem cells in regenerative medicine for Parkinson's and Huntington's Diseases.
Auteurs : L. Lescaudron [France] ; P. Naveilhan ; I. NeveuSource :
- Current medicinal chemistry [ 1875-533X ] ; 2012.
English descriptors
- KwdEn :
- Animals, Dopaminergic Neurons (metabolism), Embryonic Stem Cells (cytology), Embryonic Stem Cells (transplantation), Humans, Huntington Disease (genetics), Huntington Disease (metabolism), Huntington Disease (therapy), Induced Pluripotent Stem Cells (cytology), Induced Pluripotent Stem Cells (transplantation), Mesenchymal Stromal Cells (cytology), Nerve Growth Factors (metabolism), Neural Stem Cells (cytology), Neural Stem Cells (transplantation), Parkinson Disease (genetics), Parkinson Disease (metabolism), Parkinson Disease (therapy), Regenerative Medicine, Stem Cell Transplantation, Stem Cells (cytology).
- MESH :
- chemical , metabolism : Nerve Growth Factors.
- cytology : Embryonic Stem Cells, Induced Pluripotent Stem Cells, Mesenchymal Stromal Cells, Neural Stem Cells, Stem Cells.
- genetics : Huntington Disease, Parkinson Disease.
- metabolism : Dopaminergic Neurons, Huntington Disease, Parkinson Disease.
- therapy : Huntington Disease, Parkinson Disease.
- transplantation : Embryonic Stem Cells, Induced Pluripotent Stem Cells, Neural Stem Cells.
- Animals, Humans, Regenerative Medicine, Stem Cell Transplantation.
Abstract
Cell transplantation has been proposed as a means of replacing specific cell populations lost through neurodegenerative processes such as that seen in Parkinson's or Huntington's diseases. Improvement of the clinical symptoms has been observed in a number of Parkinson and Huntington's patients transplanted with freshly isolated fetal brain tissue but such restorative approach is greatly hampered by logistic and ethical concerns relative to the use of fetal tissue, in addition to potential side effects that remain to be controlled. In this context, stem cells that are capable of self-renewal and can differentiate into neurons, have received a great deal of interest, as demonstrated by the numerous studies based on the transplantation of neural stem/progenitor cells, embryonic stem cells or mesenchymal stem cells into animal models of Parkinson's or Huntington's diseases. More recently, the induction of pluripotent stem cells from somatic adult cells has raised a new hope for the treatment of neurodegenerative diseases. In the present article, we review the main experimental approaches to assess the efficiency of cell-based therapy for Parkinson's or Huntington's diseases, and discuss the recent advances in using stem cells to replace lost dopaminergic mesencephalic or striatal neurons. Characteristics of the different stem cells are extensively examined with a special attention to their ability of producing neurotrophic or immunosuppressive factors, as these may provide a favourable environment for brain tissue repair and long-term survival of transplanted cells in the central nervous system. Thus, stem cell therapy can be a valuable tool in regenerative medicine.
PubMed: 22963567
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000900
- to stream PubMed, to step Curation: 000864
- to stream PubMed, to step Checkpoint: 000864
Links to Exploration step
pubmed:22963567Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The use of stem cells in regenerative medicine for Parkinson's and Huntington's Diseases.</title><author><name sortKey="Lescaudron, L" sort="Lescaudron, L" uniqKey="Lescaudron L" first="L" last="Lescaudron">L. Lescaudron</name><affiliation wicri:level="1"><nlm:affiliation>LUNAM Université, France. Laurent.Lescaudron@univ-nantes.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>LUNAM Université</wicri:regionArea></affiliation></author><author><name sortKey="Naveilhan, P" sort="Naveilhan, P" uniqKey="Naveilhan P" first="P" last="Naveilhan">P. Naveilhan</name></author><author><name sortKey="Neveu, I" sort="Neveu, I" uniqKey="Neveu I" first="I" last="Neveu">I. Neveu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22963567</idno><idno type="pmid">22963567</idno><idno type="wicri:Area/PubMed/Corpus">000900</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000900</idno><idno type="wicri:Area/PubMed/Curation">000864</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000864</idno><idno type="wicri:Area/PubMed/Checkpoint">000864</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000864</idno><idno type="wicri:Area/Ncbi/Merge">000F79</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The use of stem cells in regenerative medicine for Parkinson's and Huntington's Diseases.</title><author><name sortKey="Lescaudron, L" sort="Lescaudron, L" uniqKey="Lescaudron L" first="L" last="Lescaudron">L. Lescaudron</name><affiliation wicri:level="1"><nlm:affiliation>LUNAM Université, France. Laurent.Lescaudron@univ-nantes.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>LUNAM Université</wicri:regionArea></affiliation></author><author><name sortKey="Naveilhan, P" sort="Naveilhan, P" uniqKey="Naveilhan P" first="P" last="Naveilhan">P. Naveilhan</name></author><author><name sortKey="Neveu, I" sort="Neveu, I" uniqKey="Neveu I" first="I" last="Neveu">I. Neveu</name></author></analytic><series><title level="j">Current medicinal chemistry</title><idno type="eISSN">1875-533X</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Dopaminergic Neurons (metabolism)</term><term>Embryonic Stem Cells (cytology)</term><term>Embryonic Stem Cells (transplantation)</term><term>Humans</term><term>Huntington Disease (genetics)</term><term>Huntington Disease (metabolism)</term><term>Huntington Disease (therapy)</term><term>Induced Pluripotent Stem Cells (cytology)</term><term>Induced Pluripotent Stem Cells (transplantation)</term><term>Mesenchymal Stromal Cells (cytology)</term><term>Nerve Growth Factors (metabolism)</term><term>Neural Stem Cells (cytology)</term><term>Neural Stem Cells (transplantation)</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (therapy)</term><term>Regenerative Medicine</term><term>Stem Cell Transplantation</term><term>Stem Cells (cytology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Nerve Growth Factors</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Embryonic Stem Cells</term><term>Induced Pluripotent Stem Cells</term><term>Mesenchymal Stromal Cells</term><term>Neural Stem Cells</term><term>Stem Cells</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Huntington Disease</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Dopaminergic Neurons</term><term>Huntington Disease</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Huntington Disease</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Embryonic Stem Cells</term><term>Induced Pluripotent Stem Cells</term><term>Neural Stem Cells</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Regenerative Medicine</term><term>Stem Cell Transplantation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cell transplantation has been proposed as a means of replacing specific cell populations lost through neurodegenerative processes such as that seen in Parkinson's or Huntington's diseases. Improvement of the clinical symptoms has been observed in a number of Parkinson and Huntington's patients transplanted with freshly isolated fetal brain tissue but such restorative approach is greatly hampered by logistic and ethical concerns relative to the use of fetal tissue, in addition to potential side effects that remain to be controlled. In this context, stem cells that are capable of self-renewal and can differentiate into neurons, have received a great deal of interest, as demonstrated by the numerous studies based on the transplantation of neural stem/progenitor cells, embryonic stem cells or mesenchymal stem cells into animal models of Parkinson's or Huntington's diseases. More recently, the induction of pluripotent stem cells from somatic adult cells has raised a new hope for the treatment of neurodegenerative diseases. In the present article, we review the main experimental approaches to assess the efficiency of cell-based therapy for Parkinson's or Huntington's diseases, and discuss the recent advances in using stem cells to replace lost dopaminergic mesencephalic or striatal neurons. Characteristics of the different stem cells are extensively examined with a special attention to their ability of producing neurotrophic or immunosuppressive factors, as these may provide a favourable environment for brain tissue repair and long-term survival of transplanted cells in the central nervous system. Thus, stem cell therapy can be a valuable tool in regenerative medicine.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22963567</PMID><DateCreated><Year>2013</Year><Month>01</Month><Day>02</Day></DateCreated><DateCompleted><Year>2013</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-533X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>35</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>Current medicinal chemistry</Title><ISOAbbreviation>Curr. Med. Chem.</ISOAbbreviation></Journal><ArticleTitle>The use of stem cells in regenerative medicine for Parkinson's and Huntington's Diseases.</ArticleTitle><Pagination><MedlinePgn>6018-35</MedlinePgn></Pagination><Abstract><AbstractText>Cell transplantation has been proposed as a means of replacing specific cell populations lost through neurodegenerative processes such as that seen in Parkinson's or Huntington's diseases. Improvement of the clinical symptoms has been observed in a number of Parkinson and Huntington's patients transplanted with freshly isolated fetal brain tissue but such restorative approach is greatly hampered by logistic and ethical concerns relative to the use of fetal tissue, in addition to potential side effects that remain to be controlled. In this context, stem cells that are capable of self-renewal and can differentiate into neurons, have received a great deal of interest, as demonstrated by the numerous studies based on the transplantation of neural stem/progenitor cells, embryonic stem cells or mesenchymal stem cells into animal models of Parkinson's or Huntington's diseases. More recently, the induction of pluripotent stem cells from somatic adult cells has raised a new hope for the treatment of neurodegenerative diseases. In the present article, we review the main experimental approaches to assess the efficiency of cell-based therapy for Parkinson's or Huntington's diseases, and discuss the recent advances in using stem cells to replace lost dopaminergic mesencephalic or striatal neurons. Characteristics of the different stem cells are extensively examined with a special attention to their ability of producing neurotrophic or immunosuppressive factors, as these may provide a favourable environment for brain tissue repair and long-term survival of transplanted cells in the central nervous system. Thus, stem cell therapy can be a valuable tool in regenerative medicine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lescaudron</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>LUNAM Université, France. Laurent.Lescaudron@univ-nantes.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naveilhan</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Neveu</LastName><ForeName>I</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Curr Med Chem</MedlineTA><NlmUniqueID>9440157</NlmUniqueID><ISSNLinking>0929-8673</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stromal Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058953" MajorTopicYN="N">Neural Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044968" MajorTopicYN="N">Regenerative Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>02</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>05</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22963567</ArticleId><ArticleId IdType="pii">CMC-EPUB-20120903-38</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Naveilhan, P" sort="Naveilhan, P" uniqKey="Naveilhan P" first="P" last="Naveilhan">P. Naveilhan</name><name sortKey="Neveu, I" sort="Neveu, I" uniqKey="Neveu I" first="I" last="Neveu">I. Neveu</name></noCountry><country name="France"><noRegion><name sortKey="Lescaudron, L" sort="Lescaudron, L" uniqKey="Lescaudron L" first="L" last="Lescaudron">L. Lescaudron</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F79 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000F79 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:22963567
|texte= The use of stem cells in regenerative medicine for Parkinson's and Huntington's Diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22963567" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |